Skip to Main Content

The Faculty of Medicine - Immunology and Cancer Research: Lotem Michal


Last updated September 2023 -  Immunology and Cancer Research

List of Publications


Robert C, Carlino MS, McNeil C, Ribas A, Grob JJ, Schachter J, et al. Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma. Journal of Clinical Oncology [Internet]. 2023;41(24):3998–4003. Available from:


Talmon A, Elias S, Rubin L, Ribak Y, Ben Dori E, Shamriz O, et al. Dupilumab for cancer-associated refractory pruritus. Journal of Allergy and Clinical Immunology: Global [Internet]. 2023;2(3). Available from:


Friedman N, Weinstein-Fudim L, Mostinski Y, Elia J, Cohen S, Steinberg E, et al. Preventing skin toxicities induced by EGFR inhibitors by topically blocking drug-receptor interactions. Science Translational Medicine [Internet]. 2023;15(699). Available from:


Stejerean-Todoran I, Gimotty PA, Watters A, Brafford P, Krepler C, Godok T, et al. A distinct pattern of growth and RAC1 signaling in melanoma brain metastasis cells. Neuro-Oncology [Internet]. 2023;25(4):674–86. Available from:


Babiker H, Borazenci E, Subbiah V, Agarwala S, Algazi A, Schachter J, et al. Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101). Clinical Cancer Research [Internet]. 2022;28(23):5079–87. Available from:


Molho-Pessach V, Hartshtark S, Merims S, Lotem M, Caplan N, Alfassi H, et al. Giant congenital melanocytic naevus with a novel CUX1–BRAF fusion mutation treated with trametinib. British Journal of Dermatology [Internet]. 2022;187(6):1052–4. Available from:


Shreberk-Hassidim R, Geiger-Maor A, Eisenberg G, Merims S, Hajaj E, Cohen JE, et al. The role of immune checkpoint receptors in the malignant phenotype of cutaneous T cell lymphoma. Immunologic Research [Internet]. 2022;70(6):793–9. Available from:


Sidlik Muskatel R, Pillar N, Godefroy J, Lotem M, Goldstein G. Case report: Robust response of metastatic clear cell sarcoma treated with cabozantinib and immunotherapy. Frontiers in Pediatrics [Internet]. 2022;10. Available from:


Shreberk-Hassidim R, Aizenbud L, Lussheimer S, Thomaidou E, Bdolah-Abram T, Merims S, et al. Dermatological adverse events under programmed cell death-1 inhibitors as a prognostic marker in metastatic melanoma. Dermatologic Therapy [Internet]. 2022;35(10). Available from:


Zer A, Icht O, Yosef L, Avram D, Jacobi O, Fenig E, et al. Phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (cKS). Annals of Oncology [Internet]. 2022;33(7):720–7. Available from:


Labes S, Stupp D, Wagner N, Bloch I, Lotem M, Lahad EL, et al. Machine-learning of complex evolutionary signals improves classification of SNVs. NAR Genomics and Bioinformatics [Internet]. 2022;4(2). Available from:


Ronen D, Bsoul A, Lotem M, Abedat S, Yarkoni M, Amir O, et al. Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies. Vaccines [Internet]. 2022;10(4). Available from:


Long GV, Arance A, Mortier L, Lorigan P, Blank C, Mohr P, et al. Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006. Annals of Oncology [Internet]. 2022;33(2):204–15. Available from:


Dalle S, Mortier L, Corrie P, Lotem M, Board R, Arance AM, et al. Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study. BMC Cancer [Internet]. 2021;21(1). Available from:


Avner M, Orevi M, Caplan N, Popovtzer A, Lotem M, Cohen JE. COVID-19 vaccine as a cause for unilateral lymphadenopathy detected by 18F-FDG PET/CT in a patient affected by melanoma. European Journal of Nuclear Medicine and Molecular Imaging [Internet]. 2021;48(8):2659–60. Available from:


Hajaj E, Zisman E, Tzaban S, Merims S, Cohen J, Klein S, et al. Alternative splicing of the inhibitory immune checkpoint receptor SLAMF6 generates a dominant positive form, boosting T-cell effector functions. Cancer Immunology Research [Internet]. 2021;9(6):637–50. Available from:


Ghosh S, Nataraj NB, Noronha A, Patkar S, Sekar A, Mukherjee S, et al. PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR. Cell Reports [Internet]. 2021;35(8). Available from:


Bottomley A, Coens C, Mierzynska J, Blank CU, Mandalà M, Long GV, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. The Lancet Oncology [Internet]. 2021;22(5):655–64. Available from:


Eggermont AMM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. The Lancet Oncology [Internet]. 2021;22(5):643–54. Available from:


Maddalena M, Mallel G, Nataraj NB, Shreberk-Shaked M, Hassin O, Mukherjee S, et al. TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment. Proceedings of the National Academy of Sciences of the United States of America [Internet]. 2021;118(23). Available from:


Kalaora S, Nagler A, Nejman D, Alon M, Barbolin C, Barnea E, et al. Identification of bacteria-derived HLA-bound peptides in melanoma. Nature [Internet]. 2021;592(7852):138–43. Available from:


Peri A, Greenstein E, Alon M, Pai JA, Dingjan T, Reich-Zeliger S, et al. Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma. Journal of Clinical Investigation [Internet]. 2021;131(20). Available from:


Ferrucci PF, Di Giacomo AM, Del Vecchio M, Atkinson V, Schmidt H, Schachter J, et al. KEYNOTE-022 part 3: A randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. Journal for ImmunoTherapy of Cancer [Internet]. 2020;8(2). Available from:


Kalaora S, Lee JS, Barnea E, Levy R, Greenberg P, Alon M, et al. Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma. Nature Communications [Internet]. 2020;11(1). Available from:


Kucukkaraduman B, Turk C, Fallacara AL, Isbilen M, Senses KM, Ayyildiz ZO, et al. Predictive Gene Signature for Pyrazolopyrimidine Derivative c-Src Inhibitor 10a Sensitivity in Melanoma Cells. ACS Medicinal Chemistry Letters [Internet]. 2020;11(5):928–32. Available from:


Hirshoren N, Yoeli R, Cohen JE, Weinberger JM, Kaplan N, Merims S, et al. Checkpoint inhibitors: Better outcomes among advanced cutaneous head and neck melanoma patients. PLoS ONE [Internet]. 2020;15(4). Available from:


Hajaj E, Eisenberg G, Klein S, Frankenburg S, Merims S, David IB, et al. SLAMF6 deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint. eLife [Internet]. 2020;9. Available from:


Hadash-Bengad R, Hajaj E, Klein S, Merims S, Frank S, Eisenberg G, et al. Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanoma—A Retrospective Study. Frontiers in Oncology [Internet]. 2020;10. Available from:


Tsur N, Kogan Y, Avizov-Khodak E, Vaeth D, Vogler N, Utikal J, et al. Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm. Journal of Translational Medicine [Internet]. 2019;17(1). Available from:


Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. The Lancet Oncology [Internet]. 2019;20(9):1239–51. Available from:


Pollack RM, Kagan M, Lotem M, Dresner-Pollak R. Baseline TSH level is associated with risk of anti–PD-1–induced thyroid dysfunction. Endocrine Practice [Internet]. 2019;25(8):824–9. Available from:


Ascierto PA, Ferrucci PF, Fisher R, Del Vecchio M, Atkinson V, Schmidt H, et al. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nature Medicine [Internet]. 2019;25(6):941–6. Available from:


Boussemart L, Johnson A, Schrock AB, Pal SK, Frampton GM, Fabrizio D, et al. Tumor mutational burden and response to programmed cell death protein 1 inhibitors in a case series of patients with metastatic desmoplastic melanoma. Journal of the American Academy of Dermatology [Internet]. 2019;80(6):1780–2. Available from:


Weinstein-Marom H, Levin N, Pato A, Shmuel N, Sharabi-Nov A, Peretz T, et al. Combined Expression of Genetic Adjuvants Via mRNA Electroporation Exerts Multiple Immunostimulatory Effects on Antitumor T Cells. Journal of Immunotherapy [Internet]. 2019;42(2):43–50. Available from:


Levin N, Weinstein-Marom H, Pato A, Itzhaki O, Besser MJ, Eisenberg G, et al. Potent Activation of Human T Cells by mRNA Encoding Constitutively Active CD40. Journal of Immunology [Internet]. 2018;201(10):2959–68. Available from:


Kalaora S, Wolf Y, Feferman T, Barnea E, Greenstein E, Reshef D, et al. Combined analysis of antigen presentation and T-cell recognition reveals restricted immune responses in melanoma. Cancer Discovery [Internet]. 2018;8(11):1366–75. Available from:


Filippou PS, Ren AH, Korbakis D, Dimitrakopoulos L, Soosaipillai A, Barak V, et al. Exploring the potential of mucin 13 (MUC13) as a biomarker for carcinomas and other diseases. Clinical Chemistry and Laboratory Medicine [Internet]. 2018;56(11):1945–53. Available from:


Fellner A, Makranz C, Lotem M, Bokstein F, Taliansky A, Rosenberg S, et al. Neurologic complications of immune checkpoint inhibitors. Journal of Neuro-Oncology [Internet]. 2018;137(3):601–9. Available from:


Eisenberg G, Engelstein R, Geiger-Maor A, Hajaj E, Merims S, Frankenburg S, et al. Soluble SLAMF6 receptor induces strong CD8\+ T-cell effector function and improves anti-melanoma activity in vivo. Cancer Immunology Research [Internet]. 2018;6(2):127–38. Available from:


Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, et al. Predictors of responses to immune checkpoint blockade in advanced melanoma. Nature Communications [Internet]. 2017;8(1). Available from:


Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). The Lancet [Internet]. 2017;390(10105):1853–62. Available from:


Zick A, Peretz T, Lotem M, Hubert A, Katz D, Temper M, et al. Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients. Medicine (United States) [Internet]. 2017;96(20). Available from:


Cohen JE, Merims S, Frank S, Engelstein R, Peretz T, Lotem M. Adoptive cell therapy: Past, present and future. Immunotherapy [Internet]. 2017;9(2):183–96. Available from:


Senses KM, Ghasemi M, Akbar MW, Isbilen M, Fallacara AL, Frankenburg S, et al. Phenotype-based variation as a biomarker of sensitivity to molecularly targeted therapy in melanoma. MedChemComm [Internet]. 2017;8(1):88–95. Available from:


Kuint R, Lotem M, Neuman T, Bekker-Milovanov E, Abutbul A, Laxer U, et al. Organizing pneumonia following treatment with pembrolizumab for metastatic malignant melanoma – A case report. Respiratory Medicine Case Reports [Internet]. 2017;20:95–7. Available from:


Levin N, Pato A, Cafri G, Eisenberg G, Peretz T, Margalit A, et al. Spontaneous Activation of Antigen-presenting Cells by Genes Encoding Truncated Homo-Oligomerizing Derivatives of CD40. Journal of Immunotherapy [Internet]. 2017;40(2):39–50. Available from:


Sade-Feldman M, Kanterman J, Klieger Y, Ish-Shalom E, Olga M, Saragovi A, et al. Clinical significance of circulating CD33+ CD11bHLA-DR myeloid cells in patients with stage IV melanoma treated with ipilimumab. Clinical Cancer Research [Internet]. 2016;22(23):5661–72. Available from:


Engelstein R, Merims S, Eisenberg G, Cohen J, Frank S, Hamburger T, et al. Immune monitoring of patients treated with a whole-cell melanoma vaccine engineered to express 4-1BBL. Journal of Immunotherapy [Internet]. 2016;39(8):321–8. Available from:


Ollech A, Stemmer SM, Merims S, Lotem M, Popovtzer A, Hendler D, et al. Widespread morbilliform rash due to sorafenib or vemurafenib treatment for advanced cancer; experience of a tertiary dermato-oncology clinic. International Journal of Dermatology [Internet]. 2016;55(4):473–8. Available from:


Lotem M, Merims S, Frank S, Hamburger T, Nissan A, Kadouri L, et al. Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade. Journal of Immunology Research [Internet]. 2016;2016. Available from:


Weinstein-Marom H, Pato A, Levin N, Susid K, Itzhaki O, Besser MJ, et al. Membrane-attached cytokines expressed by mRNA electroporation act as potent T-cell adjuvants. Journal of Immunotherapy [Internet]. 2016;39(2):60–70. Available from:


Barak V, Leibovici V, Peretz T, Kalichman I, Lotem M, Merims S. Assessing Response to New Treatments and Prognosis in Melanoma Patients, by the Biomarker S-100β. Anticancer research [Internet]. 2015;35(12):6755–60. Available from:


Pato A, Eisenberg G, Machlenkin A, Margalit A, Cafri G, Frankenburg S, et al. Messenger RNA encoding constitutively active Toll-like receptor 4 enhances effector functions of human T cells. Clinical and Experimental Immunology [Internet]. 2015;182(2):220–9. Available from:


Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. New England Journal of Medicine [Internet]. 2015;372(26):2521–32. Available from:


Uzana R, Eisenberg G, Merims S, Frankenburg S, Pato A, Yefenof E, et al. Human T cell crosstalk is induced by tumor membrane transfer. PLoS ONE [Internet]. 2015;10(2). Available from:


Shtivelman E, Davies MA, Hwu P, Yang J, Lotem M, Oren M, et al. Pathways and therapeutic targets in melanoma. Oncotarget [Internet]. 2014;5(7):1701–52. Available from:


Eisenberg G, Uzana R, Pato A, Frankenburg S, Merims S, Yefenof E, et al. Imprinting of lymphocytes with melanoma antigens acquired by trogocytosis facilitates identification of tumor-reactive T cells. Journal of Immunology [Internet]. 2013;190(11):5856–65. Available from:


Yaacov B, Lazar I, Tayeb S, Frank S, Izhar U, Lotem M, et al. Extracellular matrix constituents interfere with Newcastle disease virus spread in solid tissue and diminish its potential oncolytic activity. Journal of General Virology [Internet]. 2012;93(8):1664–72. Available from:


Lazar I, Perlman R, Lotem M, Peretz T, Ben-Yehuda D, Kadouri L. The clinical effect of the inhibitor of apopotosis protein livin in melanoma. Oncology [Internet]. 2012;82(4):197–204. Available from:


Uzana R, Eisenberg G, Sagi Y, Frankenburg S, Merims S, Amariglio N, et al. Trogocytosis is a gateway to characterize functional diversity in melanoma-specific CD8 + T cell clones. Journal of Immunology [Internet]. 2012;188(2):632–40. Available from:


Lotem M, Merims S, Frank S, Ospovat I, Peretz T. [Ctla-4 blockade: a new hope for the immunotherapy of malignant melanoma]. Harefuah [Internet]. 2012;151(10):585–8, 604. Available from:


Lotem M, Kadouri L, Merims S, Ospovat I, Nissan A, Ron I, et al. HLA-B35 correlates with a favorable outcome following adjuvant administration of an HLA-matched allogeneic melanoma vaccine. Tissue Antigens [Internet]. 2011;78(3):203–7. Available from:


Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New England Journal of Medicine [Internet]. 2011;364(26):2517–26. Available from:


Eisenberg G, Machlenkin A, Frankenburg S, Mansura A, Pitcovski J, Yefenof E, et al. Transcutaneous immunization with hydrophilic recombinant gp100 protein induces antigen-specific cellular immune response. Cellular Immunology [Internet]. 2010;266(1):98–103. Available from:


Lazar I, Yaacov B, Shiloach T, Eliahoo E, Kadouri L, Lotem M, et al. The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein livin. Journal of Virology [Internet]. 2010;84(1):639–46. Available from:


Bosch JJ, Iheagwara UK, Reid S, Srivastava MK, Wolf J, Lotem M, et al. Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8+ cytotoxic, tumor-specific T cells. Cancer Immunology, Immunotherapy [Internet]. 2010;59(1):103–12. Available from:


Lotem M, Machlenkin A, Hamburger T, Nissan A, Kadouri L, Frankenburg S, et al. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells. Clinical Cancer Research [Internet]. 2009;15(15):4968–77. Available from:


Frenkel S, Nir I, Hendler K, Lotem M, Eid A, Jurim O, et al. Long-term survival of uveal melanoma patients after surgery for liver metastases. British Journal of Ophthalmology [Internet]. 2009;93(8):1042–6. Available from:


Kadouri L, Temper M, Grenader T, Abeliovich D, Hamburger T, Peretz T, et al. Absence of founder BRCA1 and BRCA2 mutations in coetaneous malignant melanoma patients of Ashkenazi origin. Familial Cancer [Internet]. 2009;8(1):29–32. Available from:


Gross M, Maly B, Maly A, Lotem M, Eliashar R. Metastatic Malignant Melanoma Involving the Parotid Lymph Node Region: A Clinicopathologic Report of 5 Cases. Journal of Oral and Maxillofacial Surgery [Internet]. 2008;66(4):809–13. Available from:


Machlenkin A, Uzana R, Frankenburg S, Eisenberg G, Eisenbach L, Pitcovski J, et al. Capture of tumor cell membranes by trogocytosis facilitates detection and isolation of tumor-specific functional CTLs. Cancer Research [Internet]. 2008;68(6):2006–13. Available from:


Levy A, Pitcovski J, Frankenburg S, Elias O, Altuvia Y, Margalit H, et al. A melanoma multiepitope polypeptide induces specific CD8+ T-cell response. Cellular Immunology [Internet]. 2007;250(1–2):24–30. Available from:


Molho-Pessach V, Lotem M. Ultraviolet radiation and cutaneous carcinogenesis. Current Problems in Dermatology [Internet]. 2007;35:14–27. Available from:


Molho-Pessach V, Lotem M. Viral carcinogenesis in skin cancer. Current Problems in Dermatology [Internet]. 2007;35:39–51. Available from:


Bosch JJ, Thompson JA, Srivastava MK, Iheagwara UK, Murray TG, Lotem M, et al. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4+ T lymphocytes that cross-react with primary and metastatic uveal melanoma cells. Cancer Research [Internet]. 2007;67(9):4499–506. Available from:


Salah Z, Maoz M, Pokroy E, Lotem M, Bar-Shavit R, Uziely B. Protease-activated receptor-1 (hPar1), a survival factor eliciting tumor progression. Molecular Cancer Research [Internet]. 2007;5(3):229–40. Available from:


Lotem M, Zhao Y, Riley J, Hwu P, Morgan RA, Rosenberg SA, et al. Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors. Journal of Immunotherapy [Internet]. 2006;29(6):616–27. Available from:


Peters S, Voelter V, Zografos L, Pampallona S, Popescu R, Gillet M, et al. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: Experience in 101 patients. Annals of Oncology [Internet]. 2006;17(4):578–83. Available from:


Enk CD, Lotem M, Gimon Z, Hochberg M. Molecular detection of MART-1, tyrosinase and MIA in peripheral blood, lymph nodes and metastatic sites of stage III/IV melanoma patients. Melanoma Research [Internet]. 2004;14(5):361–5. Available from:


Frankenburg S, Elias O, Gelbart Y, Drize O, Lotem M, Ingber A, et al. Recombinant hydrophilic human gp100: Uptake by dendritic cells and stimulation of autologous CD8+ lymphocytes from melanoma patients. Immunology Letters [Internet]. 2004;94(3):253–9. Available from:


Hodak E, Gottlieb AB, Segal T, Maron L, Lotem M, Feinmesser M, et al. An open trial of climatotherapy at the dead sea for patch-stage mycosis fungoides. Journal of the American Academy of Dermatology [Internet]. 2004;51(1):33–8. Available from:


Lotem M, Shiloni E, Pappo I, Drize O, Hamburger T, Weitzen R, et al. Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma. British Journal of Cancer [Internet]. 2004;90(4):773–80. Available from:


Lieberman S, Goldin E, Lotem M, Bloom AI. Irrigation of the bile ducts with chilled saline during percutaneous radiofrequency ablation of a hepatic ocular melanoma metastasis. American Journal of Roentgenology [Internet]. 2004;183(3):596–8. Available from:


Gelbart Y, Frankenburg S, Pinchasov Y, Krispel S, Eliahu D, Drize O, et al. Production and purification of melanoma gp100 antigen and polyclonal antibodies. Protein Expression and Purification [Internet]. 2004;34(2):183–9. Available from:


Nachmias B, Ashhab Y, Bucholtz V, Drize O, Kadouri L, Lotem M, et al. Caspase-mediated cleavage converts livin from an antiapoptotic to a proapoptotic factor: Implications for drug-resistant melanoma. Cancer Research [Internet]. 2003;63(19):6340–9. Available from:


Lotem M, Yehuda-Gafni O, Butnaryu E, Drize O, Peretz T, Abeliovich D. Cytogenetic analysis of melanoma cell lines: Subclone selection in long-term melanoma cell cultures. Cancer Genetics and Cytogenetics [Internet]. 2003;142(2):87–91. Available from:


Lotem M, Anteby S, Peretz T, Ingber A, Avinoach I, Prus D. Mucosal melanoma of the female genital tract is a multifocal disorder. Gynecologic Oncology [Internet]. 2003;88(1):45–50. Available from:


Lotem M, Peretz T, Drize O, David IB, Hamburger T, Gimmon Z. Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). British Journal of Cancer [Internet]. 2002;86(10):1534–9. Available from:


Hochberg M, Lotem M, Gimon Z, Shiloni E, Enk CD. Expression of tyrosinase, MIA and MART-1 in sentinel lymph nodes of patients with malignant melanoma. British Journal of Dermatology [Internet]. 2002;146(2):244–9. Available from:


Markel G, Lieberman N, Katz G, Arnon TI, Lotem M, Drize O, et al. CD66a interactions between human melanoma and NK cells: A novel class I MHC-independent inhibitory mechanism of cytotoxicity. Journal of Immunology [Internet]. 2002;168(6):2803–10. Available from:


Lotem M, Peretz T, Drize O, David IB, Hamburger T, Gimmon Z. Special section on nonparametric approach to time series analysis. Annals of the Institute of Statistical Mathematics [Internet]. 2002;54(1):169. Available from:


Lotem M, Raben M, Zeltser R, Landau M, Sela M, Wygoda M, et al. Kindler syndrome complicated by squamous cell carcinoma of the hard palate: Successful treatment with high-dose radiation therapy and granulocyte-macrophage colony-stimulating factor [18]. British Journal of Dermatology [Internet]. 2001;144(6):1284–6. Available from:


Pappo I, Lotem M, Klein M, Orda R. Bolus high dose interleukin-2 for the treatment of malignant melanoma. Israel Medical Association Journal [Internet]. 2001;3(3):169–73. Available from:


Hazzan D, Reissmann P, Halak M, Resnick MB, Lotem M, Shiloni E. Primary rectal malignant melanoma: Report of two cases. Techniques in Coloproctology [Internet]. 2001;5(1):51–4. Available from:


Yakobson E, Shemesh P, Azizi E, Winkler E, Lassam N, Hogg D, et al. Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families. European Journal of Human Genetics [Internet]. 2000;8(8):590–6. Available from:


Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing NI, Lotem M, et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (doxil) in metastatic breast carcinoma. Cancer [Internet]. 2000;89(5):1037–47. Available from:


Lotem M, Hubert A, Lyass O, Goldenhersh MA, Ingber A, Peretz T, et al. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Archives of Dermatology [Internet]. 2000;136(12):1475–80. Available from:


Klein M, Freedman N, Lotem M, Marciano R, Moshe S, Gimon Z, et al. Contribution of whole body F-18-FDG-PET and lymphoscintigraphy to the assessment of regional and distant metastases in cutaneous malignant melanoma: A pilot study. NuklearMedizin [Internet]. 2000;39(3):56–61. Available from:


Hirshberg B, Kramer MR, Lotem M, Barak V, Shustin L, Amir G, et al. Chronic eosinophilic pneumonia associated with cutaneous T-cell lymphoma. American Journal of Hematology [Internet]. 1999;60(2):143–7. Available from:


Lotem M, Shiloni E, Ingber A, Peretz T. Active specific immunotherapy of malignant melanoma. Harefuah [Internet]. 1997;133(3–4):122–6. Available from:


Tsur A, Sazbon L, Lotem M. Relationship between muscular tone, movement and periarticular new bone formation in postcoma-unaware (PC-U) patients. Brain Injury [Internet]. 1996;10(4):259–62. Available from:


Lotem M, Tamir G, Loven D, David M, Hauben D. Multiple basal cell carcinomas of the leg after recurrent erysipelas and chronic lymphedema. Journal of the American Academy of Dermatology [Internet]. 1994;31(5):812–3. Available from:


Lotem M, Trattner A, Ingber A. Paraneoplastic Pemphigus: Reevaluation of a Case From the Past. Archives of Dermatology [Internet]. 1994;130(11):1454. Available from:


Tsur A, Sazbon L, Lotem M. Influence of muscle tone and force on ossification in postcomatose patients. Harefuah [Internet]. 1992;123(3–4):86–9, 156–7. Available from:




Lotem M, Birch JG, Herring JA, Roach JW, Johnston II CE, Viere RG. Letter to the editor [3]. Journal of Bone and Joint Surgery - Series A [Internet]. 1991;73(3):472. Available from:


Lotem M, Ingber A, Segal R, Sandbank M. Generalized pustular drug rash induced by hydroxychloroquine. Acta Dermato-Venereologica [Internet]. 1990;70(3):250–1. Available from:


Katzenelson V, Lotem M, Sandbank M. Familial lichen planus. Dermatologica [Internet]. 1990;180(3):166–8. Available from:


Halevy S, Arie R, Ingber A, Lotem M, Sandbank M. Analysis of lithogenous factors in lichen planus. Acta Dermato-Venereologica [Internet]. 1990;70(5):441–2. Available from:


Lotem M, Ingber A, Sandbank M, Hazaz B. Lichen Planus Pemphigoides With Features of Lichen Planus and Pemphigus Vulgaris. Archives of Dermatology [Internet]. 1989;125(5):707–8. Available from:


Lotem M, Katzenelson V, Sandbank M, Hod M, Sandbank M. Impetigo herpetiformis: A variant of pustular psoriasis or a separate entity? Journal of the American Academy of Dermatology [Internet]. 1989;20(2):338–41. Available from:


Lotem M, Ingber A, Filhaber A, Sandbank M. Skin infection provoked by coagulase-negative Staphylococcus resembling gram-negative folliculitis. Cutis [Internet]. 1988;42(5):443–4. Available from:


Davidovitch E, Lotem M, Hallel T. Malignant fibrous histiocytoma. Harefuah [Internet]. 1988;115(1–2):13–5. Available from:


Sagiv P, Lotem M, Solan H, Hallel T. Metatarsus adductus–incidence and treatment. Harefuah [Internet]. 1986;110(8):394–7. Available from:


Houpt JB, Alpert B, Lotem M, Greyson ND, Pritzker KP, Langer F, et al. Spontaneous osteonecrosis of the medial tibial plateau. Journal of Rheumatology [Internet]. 1982;9(1):81–90. Available from:


Groswasser Z, Lotem M, Mendelson L. Treatment of femoral fractures in patients with craniocerebral injury. International Surgery [Internet]. 1982;67(4 Suppl.):556–8. Available from:


Greyson ND, Lotem MM, Gross AE, Houpt JB. Radionuclide evaluation of spontaneous femoral osteonecrosis. Radiology [Internet]. 1982;142(3):729–35. Available from:


Lotem M, Davidovitz E. Malignant fibrous histiocytoma. Harefuah [Internet]. 1980;98(5):216-218+239. Available from:


Conforty B, Lotem M. Ossicles in human menisci: report of two cases. Clinical Orthopaedics and Related Research [Internet]. 1979;(144):272–5. Available from:


Lotem M, Bernheim J, Conforty B. Spontaneous rupture of tendons. A complication of hemodialyzed patients treated for renal failure. Nephron [Internet]. 1978;21(4):201–8. Available from:


Lotem M. Medical aspects and prevention of road accidents and the treatment of the injured. Family Physician [Internet]. 1976;5(3):36. Available from:


Lotem M, Conforty B. High pressure injection injuries of the hand (Hebrew). Harefuah [Internet]. 1975;89(5):213-215+239. Available from:


Lotem M, Wolloch J. Postoperative peripheral nerve injury. Harefuah [Internet]. 1975;88(8):379–80. Available from:


Lotem M, Solzi P. The carpal tunnel syndrome (Hebrew). Family Physician [Internet]. 1975;5(1):61-63+12. Available from:


Lotem M, Robson MD, Rosenfeld JB. Spontaneous rupture of the quadriceps tendon in patients on chronic haemodialysis. Annals of the Rheumatic Diseases [Internet]. 1974;33(5):428–9. Available from:


Lotem M, Maor P, Levi M. Rupture of the extensor tendons of the hand in lupus erythematosus disseminatus. Annals of the Rheumatic Diseases [Internet]. 1973;32(5):457–9. Available from:


Levy M, Pauker M, Lotem M, Seelenfreund M, Fried A. High tibial osteotomy: a follow up study and description of a modified technic. CLINORTHOP [Internet]. 1973;93:274–7. Available from:


Pauker M, Lotem M, Levy M, Luria M. BCG arthritis and osteomyelitis. Harefuah [Internet]. 1972;83(10):429–32. Available from:


Lotem M, Fried A, Solzi P, Natanson T. Saturday night palsy. Harefuah [Internet]. 1972;83(8):328. Available from:


Maor P, Levy M, Lotem M, Fried A. Iatrogenic Volkmann’s ischemia–a result of pressure-transfusion. International Surgery [Internet]. 1972;57(5):415–6. Available from:


Fried A, Lotem M. Local infiltration anesthesia for meniscectomy. Clinical orthopaedics and related research [Internet]. 1972;87:204–5. Available from:


Lotem M, Maor P, Fried A. Posterior interosseous nerve palsy. Harefuah [Internet]. 1971;81(8):377–9. Available from:


Lotem M, Fried A. Operative treatment of degenerative tears of the semilunar cartilage. A follow-up study. Israel Journal of Medical Sciences [Internet]. 1971;7(6):733–7. Available from:


Lotem M, Maor P, Haimoff H, Woloch Y. Lumbar hernia at an iliac bone graft donor site. A case report. Clinical orthopaedics and related research [Internet]. 1971;80:130–2. Available from:


Lotem M, Fried A, Levy M, Solzi P, Najenson T, Nathan H. Radial palsy following muscular effort. A nerve compression syndrome possibly related to a fibrous arch of the lateral head of the triceps. The Journal of bone and joint surgery British volume [Internet]. 1971;53(3):500–6. Available from:


Lotem M, Solsi P. Transient radial palsy following muscular effort. Harefuah [Internet]. 1970;78(10):490–1. Available from:


Levy M, Lotem M, Fried A. The Laurence-Moon-Biedl-Bardet syndrome. Report of three cases in a Jewish Yemenite family. The Journal of bone and joint surgery British volume [Internet]. 1970;52(2):318–24. Available from: